176750 — Duchembio Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapNeutral

Annual income statement for Duchembio Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	ARS	Annual Audited Accounts	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	10,985	32,422	34,695	35,601	38,572
Cost of Revenue
Gross Profit	3,201	8,699	11,797	12,234	14,230
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	10,533	32,057	29,470	30,525	31,202
Operating Profit	452	366	5,225	5,076	7,370
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	1,447	-2,697	4,052	5,564	6,656
Provision for Income Taxes
Net Income After Taxes	1,447	-2,832	4,001	7,994	6,480
Minority Interest
Net Income Before Extraordinary Items
Net Income	1,520	-2,601	4,001	7,994	6,480
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	1,520	-2,601	4,001	7,994	6,480
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	56.9	-23.8	150	298	230
Dividends per Share